Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on developing cancer treatments, announced that its management team will present an overview of the company at ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.38 ...

Cellectar Biosciences will announce Q1 2025 financial results and corporate updates on May 13, 2025, at 8:30 a.m. ET. Cellectar Biosciences, Inc. has announced that it will release its financial ...

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through ...

FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and ...

On Tuesday, Cellectar Biosciences, Inc. (NASDAQ:CLRB) unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) stock is trading higher on Wednesday. As per data from Benzinga Pro, session volume stands at 361.96 million versus an average volume of 968.03k. What ...

Cellectar Biosciences Inc. advanced stock charts by Barron's. View NV4 historical stock data and compare to other stocks, and exchanges.

Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.17. Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Call Transcript August 13, 2024 Operator: Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call ...